Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
04:22:24 EDT Sun 13 Jul 2025
Enter Symbol
or Name
USA
CA



Q:INCY - INCYTE CORPORATION - https://www.incyte.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
INCY - Q0.160.54·74.732.568.59-1.75-2.51,094.874,36816,18069.66  69.975  68.3683.94  53.5617:25:28Jul 1015 min RT 2¢

Recent Trades - Last 10 of 16180
Time ETExPriceChangeVolume
17:25:28Q68.59-1.759,270
17:22:05Q66.20-4.141
16:50:12Q68.59-1.7526
16:20:00Q68.59-1.75169
16:04:11Q68.59-1.751
16:04:11Q68.59-1.751
16:04:10Q68.59-1.751
16:04:10Q68.59-1.751
16:04:09Q68.59-1.751
16:04:08Q68.59-1.751

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-07-10 08:00U:INCYNews ReleaseIncyte to Report Second Quarter Financial Results
2025-07-02 16:30U:INCYNews ReleaseIncyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2025-06-26 07:30U:INCYNews ReleaseIncyte Appoints Bill Meury Chief Executive Officer; Herve Hoppenot to Retire
2025-06-20 16:30U:INCYNews ReleaseUpdate on FDA Review of Ruxolitinib Cream (Opzelura(TM)) for Children Ages 2-11 with Atopic Dermatitis
2025-06-18 15:39U:INCYNews ReleaseIncyte Announces FDA Approval of Monjuvi(TM) (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma
2025-06-15 04:00U:INCYNews ReleaseQIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)
2025-06-15 03:15U:INCYNews ReleasePositive Late-Breaking Data for Incyte's First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025
2025-06-12 18:45U:INCYNews ReleasePhase 3 Data for Incyte's Retifanlimab (Zynyz(TM)) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet
2025-06-06 16:30U:INCYNews ReleaseIncyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-06-03 10:30U:INCYNews ReleaseIncyte Announces Multiple Presentations, Including New Late-Breaking Data for its mutCALR-Directed Monoclonal Antibody (INCA033989), Accepted for Presentation at EHA 2025
2025-05-27 08:00U:INCYNews ReleaseIncyte to Present at Upcoming Investor Conference
2025-05-15 14:30U:INCYNews ReleaseIncyte Announces FDA Approval of Zynyz(TM) (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States
2025-05-07 16:30U:INCYNews ReleaseIncyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-05-01 08:00U:INCYNews ReleaseIncyte to Present at Upcoming Investor Conference
2025-04-29 07:00U:INCYNews ReleaseIncyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs
2025-04-25 08:00U:INCYNews ReleaseIncyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 2025
2025-04-23 11:03U:INCYNews ReleaseIncyte to Showcase New Data from its Oncology Portfolio at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
2025-04-10 08:00U:INCYNews ReleaseIncyte to Report First Quarter Financial Results
2025-04-07 16:30U:INCYNews ReleaseIncyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-03-26 07:30U:INCYNews ReleaseKnight Therapeutics Announces Launch of Minjuvi(TM) (tafasitamab) in Mexico